Progenics Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, October 2011, Pages: 101

Progenics Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Progenics Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Progenics Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Progenics Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Progenics Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Progenics Pharmaceuticals, Inc. - Brief Progenics Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Progenics Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Progenics Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Progenics Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Progenics Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Progenics Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Progenics Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Progenics Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Progenics Pharmaceuticals, Inc. and identify potential opportunities in those areas.

List of Tables
List of Figures
Progenics Pharmaceuticals, Inc. Snapshot
Progenics Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Progenics Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Progenics Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Progenics Pharmaceuticals, Inc. – Pipeline Products Glance
Progenics Pharmaceuticals, Inc. – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Progenics Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Progenics Pharmaceuticals, Inc. – Drug Profiles
Clostridium Difficile Antibodies
Product Description
Mechanism of Action
R&D Progress
Methylnaltrexone
Product Description
Mechanism of Action
R&D Progress
Progenics Pharmaceuticals, Inc. – Pipeline Analysis
Progenics Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Progenics Pharmaceuticals, Inc. - Pipeline Products By Target
Progenics Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Progenics Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Progenics Pharmaceuticals, Inc. – Recent Pipeline Updates
Progenics Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
PRO 206
Progenics Pharmaceuticals, Inc. – Company Statement
Progenics Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Aug 31, 2010: Progenics Pharmaceuticals To Present Preclinical Study Of Novel Monoclonal Antibodies Against C. difficile At 2010 ICAAC
May 31, 2007: Progenics And Wyeth Announce FDA Has Accepted For Filing The New Drug Application For Subcutaneous Methylnaltrexone
Aug 30, 2011: Progenics And Salix Announce FDA Acceptance Of sNDA Filing For RELISTOR In Patients With Non-Cancer Pain
Sep 29, 2010: Progenics Announces Approvals Of Pre-Filled Syringes For RELISTOR In US, EU And Canada
Jun 28, 2011: Progenics Submits RELISTOR Supplemental NDA For Treatment Of Opioid-Induced Constipation In Patients With Chronic, Non-Cancer Pain
Sep 27, 2010: Progenics Extends Agreement with Pfizer for Relistor Commercialization
May 27, 2010: Progenics Presents Novel Monoclonal Antibodies Against Clostridium Difficile At The American Society For Microbiology Conference
May 27, 2010: Progenics Presents Novel Monoclonal Antibodies Against Clostridium difficile At The American Society For Microbiology Conference
Oct 25, 2006: Progenics Earns $5 Million From Wyeth For Achieving Methylnaltrexone Milestone
May 25, 2006: Progenics Broadens Collaboration With Seattle Genetics For Prostate Cancer Therapy; Positive Preclinical Findings On PSMA Antibody-Drug Conjugate Published In Clinical Cancer Research Journal
Jan 25, 2011: Pfizer Inc and Progenics Alert Physicians and Patients to Information Related to Triad Group Alcohol Prep Products Included In U.S. Relistor Kit Packaging
Apr 24, 2008: Progenics and Wyeth Announce FDA Has Approved Relistor
Apr 24, 2008: Wyeth and Progenics Receive Positive Opinion From European Committee for Relistor for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Dec 23, 2005: Wyeth And Progenics Pharmaceuticals Announces Worldwide Collaboration To Develop And Commercialize Methylnaltrexone
Dec 23, 2005: Wyeth And Progenics Pharmaceuticals Announces Worldwide Collaboration To Develop And Commercialize Methylnaltrexone
May 23, 2006: Positive Results From Phase III Clinical Study Of Methylnaltrexone Treatment For Opioid-Induced Constipation Presented At Digestive Disease Week Conference
Feb 22, 2006: Progenics Pharmaceuticals' HIV Drug, PRO 140, Receives FDA Fast-Track Designation
Sep 21, 2010: Progenics Completes Subcutaneous Methylnaltrexone Safety Study In Chronic Non-Malignant Pain Patients
Jun 20, 2007: Wyeth And Progenics Announce Positive Preliminary Results Of Phase I Study Of New Oral Formulation Of Methylnaltrexone
May 20, 2011: Progenics Announces Results Of Methylnaltrexone Phase III Safety Study In Chronic, Non-Malignant Pain Patients
May 20, 2011: Salix Pharmaceuticals Reviews RELISTOR Data Presentations At American Pain Society Annual Meeting
Nov 17, 2008: Progenics Announces Wyeth Has Received Relistor Approval in Australia
Feb 17, 2011: Progenics Reports Positive Preliminary Data From Ongoing Phase I Clinical Study Of PSMA ADC
Nov 16, 2010: Progenics Reports Initiation Of Phase II Clinical Trial Of Subcutaneous Methylnaltrexone In Japan By Ono Pharmaceutical
Oct 16, 2008: Progenics Pharmaceuticals and Ono Pharmaceutical Announce Agreement to Develop and Commercialize Relistor in Japan
Oct 15, 2007: Wyeth And Progenics To Initiate Phase II Trials Of Oral Methylnaltrexone In Chronic-Pain Setting
Mar 15, 2010: Progenics To Advance Oral Methylnaltrexone Into Late Stage Clinical Development
Jan 15, 2008: Progenics Initiates Phase 2 Clinical Trials For PRO 140, A Novel HIV Antibody Therapy
Oct 14, 2009: Progenics Regains Worldwide Rights to Relistor Franchise
May 14, 2007: Wyeth And Progenics Pharmaceuticals Announce Submission Of Marketing Application In Europe For The Subcutaneous Formulation Of Methylnaltrexone
Sep 13, 2010: Progenics' Humanized Monoclonal Antibodies Significantly Improve Survival In An Animal Model Of C. difficile-associated Disease
Sep 11, 2007: Wyeth And Progenics Initiate New Clinical Studies To Investigate Additional Patient Populations For Methylnaltrexone
Feb 10, 2009: Progenics Selects Subcutaneous Form Of PRO 140, A Novel HIV Antibody Therapy, For Further Development
Jan 10, 2008: Progenics And Wyeth Announce NDA Review Period For Subcutaneous Methylnaltrexone Extended By Three Months
Sep 08, 2010: Progenics Initiates Oral Methylnaltrexone Phase III Trial In Patients With Chronic Non-Cancer Pain
Sep 08, 2008: Progenics Initiates Phase 1 Clinical Study Of Targeted Therapy For Prostate Cancer
Jul 08, 2002: Progenics' HIV Entry Inhibitor, Pro 542, Continues To Provide Encouraging Phase II Results
Jun 08, 2009: Progenics Provides Update On Hepatitis C Program
Jun 07, 2010: Progenics Presents Phase I PSMA ADC Study At ASCO Annual Meeting
Feb 07, 2011: Progenics Pharmaceuticals and Salix Pharmaceuticals Announce Worldwide License Agreement for Relistor.
Oct 06, 2010: Progenics Awarded $4.1 Million NIH Grant to Advance Novel C. Difficile Antibody Therapy
Mar 06, 2007: Wyeth And Progenics Begins Clinical Testing Of A New Formulation Of Oral Methylnaltrexone Based On Phase II Findings
Aug 05, 2010: Progenics Receives European Positive Opinion For RELISTOR In Pre-Filled Syringes
Aug 05, 2010: Progenics Receives Positive Opinion From CHMP For Relistor In Pre-Filled Syringes
Nov 04, 2008: Progenics Selects Small-Molecule Hepatitis C Drug Candidate For Clinical Development
Aug 04, 2009: New Delivery System for Relistor in Pre-Filled Syringes Submitted for U.S. and European Marketing Approval
Feb 04, 2010: Progenics Presents Novel Multiplex PI3-Kinase Inhibitors At American Association For Cancer Research Conference On Protein Translation and Cancer
Jul 03, 2008: Wyeth and Progenics Receive Approval from European Commission for Relistor for Opioid-Induced Constipation in Advanced Illness Patients
Nov 01, 2007: Progenics Awarded $1.9 Million In NIH Grants For Novel Prostate Cancer Therapies
Nov 01, 2007: Progenics Awarded $1.9 Million In NIH Grants For Novel Prostate Cancer Therapies
Sep 01, 1998: Progenics Funded To Pursue Fusion Protein Pro-542
Apr 01, 2008: Wyeth and Progenics Announce Relistor Receives Canadian Marketing Approval.
Financial Deals Landscape
Progenics Pharmaceuticals, Inc., Deals Summary
Progenics Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Asset Transactions
Progenics Pharmaceuticals Acquires Portion Of Royalty For methylnaltrexone
Partnerships
Progenics Pharmaceuticals Extends Its Commercialization Agreement With Wyeth Pharmaceuticals
Progenics Pharmaceuticals Enters Into Agreement With Seattle Genetics
Wyeth Enters Into Co-Development Agreement With Progenics Pharmaceuticals
Licensing Agreements
Salix Pharmaceuticals Enters Into Licensing Agreement With Progenics Pharmaceuticals For Relistor
Ono Pharmaceutical Enters Into Licensing Agreement With Progenics Pharmaceuticals
Seattle Genetics Enters Into Licensing Agreement With PSMA Development Company
Equity Offering
Progenics Pharmaceuticals Files Registration Statement For $100 Million
Progenics Pharmaceuticals Completes Public Offering Of $60 Million
Progenics Pharmaceuticals Completes Public Offering Of $60 Million
Progenics Pharmaceuticals Completes Public Offering Of $29 Million
Progenics Pharmaceuticals Completes Public Offering Of $31 Million
Acquisition
Progenics Pharmaceuticals Acquires PSMA Development Company From Cytogen
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile